For NWBO, the labeling phase is the most delicate step of all. It’s where the regulator and sponsor lock the legal language that governs indication, patient selection, dosing, warnings, manufacturing release specs, storage, and traceability. For an ATMP like a dendritic cell product, the SmPC has to fix identity and potency assays, cold chain, additional monitoring, and site traceability. Speak too soon and you risk misbranding, market abuse issues, or forcing a new review cycle. This is exactly when silence is standard.
Why it is risky to “update” mid-labeling
1. Population changes
If the regulator narrows the approved use and the company has publicly described a broader one, that mismatch can trigger corrective disclosures and more queries.
2. Evolving safety language
Premature statements that understate warnings or monitoring can be treated as promotion before authorization.
3. Manufacturing term changes
If identity or potency specs change, earlier public details become inconsistent with the final SmPC, inviting questions and delays.
4. Finalizing traceability
Pharmacovigilance and site-level tracking get set late in the process. Leaking these elements early can be viewed as disclosing confidential regulatory dialogue.
The label is not marketing copy. It is the law in a box that clinicians must practice inside. That’s why this stage is careful, quiet, and consequential.
Bullish
Market Data 
Markets 
AI
